ARTICLE | Company News
Trubion, Wyeth deal
January 9, 2006 8:00 AM UTC
Trubion granted WYE worldwide rights to TRU-015 and other Small Modular Immunopharmaceuticals (SMIPs) targeting CD20 to treat inflammatory diseases and cancer. TRU-015 is in Phase II testing to trea...